Hygeia Healthcare Holdings Co., Ltd. (6078) AI Stock Analysis

• Market Cap: HK$8.07B
• Dividend Yield: N/A
• Average Volume (3M): 7.15M
• Price to Earnings (P/E): 16.4
• Beta (1Y): 1.63
• Revenue Growth: -13.92%
• EPS Growth: -36.32%
• Country: HK
• Employees: 8,169
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.46
• Shares Outstanding: 618,499,000
• 10 Day Avg. Volume: 3,556,037
• 30 Day Avg. Volume: 7,151,771
• PEG Ratio: -1.17
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 91.66
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$18.55
• Price Target Upside: 42.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: HK$15.50 ▲(19.23% Upside)

Hygeia Healthcare's overall stock score reflects strong financial performance with robust revenue growth and profitability. However, the technical analysis indicates bearish trends, and the valuation is moderate. The lack of dividend yield and challenges in cash flow generation are notable risks.

Hygeia Healthcare Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Hygeia Healthcare Holdings Co., Limited operates as an oncology healthcare company in the People's Republic of China. The company owns and operates private for-profit hospitals that offer oncology healthcare services, such as tumor screening and genetic diagnosis, radiotherapy, surgery, chemotherapy, immunotherapy, targeted therapy, oncology rehabilitation, nutrition, and hospice care. It also provides radiotherapy center consulting services; and licenses its SRT equipment, as well as offers maintenance and technical support services for its SRT equipment. In addition, the company provides hospital and corporate management, and supply chain services. As of December 31, 2021, it operated or managed a network of 12 oncology-focused hospitals in 9 cities in 7 Provinces in the People's Republic of China. Hygeia Healthcare Holdings Co., Limited was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

Hygeia Healthcare Holdings Co., Ltd. generates revenue primarily through the provision of medical services across its network of hospitals and clinics. The company's key revenue streams include inpatient and outpatient services, particularly those related to oncology treatments such as chemotherapy, radiotherapy, and surgery. Additionally, Hygeia Healthcare benefits from strategic partnerships with medical equipment suppliers and other healthcare providers, enhancing its service offerings and operational efficiency. The company's earnings are also supported by the growing demand for specialized cancer care in China, driven by an increasing incidence of cancer and a rising middle class with access to healthcare.

Hygeia Healthcare Holdings Co., Ltd. Financial Statement Overview

Summary

Hygeia Healthcare shows strong revenue growth and profitability with a robust gross profit margin. The balance sheet is stable with manageable leverage, but the cash flow situation, particularly free cash flow generation, requires improvement to sustain long-term growth.

Income Statement

Hygeia Healthcare demonstrated strong revenue growth and profitability. The gross profit margin was robust at 29.36% for 2024, showing effective cost management. However, net profit margin decreased slightly to 13.45%, indicating some pressure on bottom-line profitability. Revenue grew by 9.06% from 2023 to 2024, showcasing continued expansion, but the slower growth compared to previous years may warrant monitoring.

Balance Sheet

The company's balance sheet reflects a healthy equity position, with a debt-to-equity ratio of 0.42 in 2024, indicating manageable leverage. Return on equity was solid at 8.99%, though slightly down from the previous year, suggesting efficient use of equity capital. The equity ratio is healthy at 60.88%, highlighting financial stability. However, increasing total debt levels could pose future risks.

Cash Flow

Cash flow analysis reveals challenges with free cash flow generation, as free cash flow was null in 2024. The operating cash flow to net income ratio is unavailable, suggesting a need for better alignment of operating cash flows to net income. The company must focus on enhancing cash flow from operations to support ongoing investments and debt obligations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.06B	4.45B	4.08B	3.20B	2.32B	1.40B
Gross Profit	827.26M	1.31B	1.29B	1.02B	744.66M	471.96M
EBITDA	588.77M	999.10M	1.11B	868.43M	623.67M	385.36M
Net Income	337.22M	598.26M	682.93M	476.78M	441.46M	170.09M
Balance Sheet
Total Assets	10.94B	10.93B	10.73B	7.24B	6.69B	4.70B
Cash, Cash Equivalents and Short-Term Investments	672.38M	651.59M	755.89M	884.71M	1.10B	2.58B
Total Debt	2.65B	2.79B	2.72B	1.29B	1.23B	2.48M
Total Liabilities	4.04B	4.25B	4.48B	2.30B	2.21B	359.93M
Stockholders Equity	6.88B	6.65B	6.23B	4.93B	4.46B	4.27B
Cash Flow
Free Cash Flow	44.76M	92.02M	-157.98M	92.26M	-236.84M	-25.77M
Operating Cash Flow	178.17M	707.13M	782.84M	685.38M	426.25M	296.13M
Investing Cash Flow	-24.67M	-671.09M	-2.86B	-372.06M	-850.85M	-2.48B
Financing Cash Flow	-87.30M	-216.56M	1.78B	-154.21M	754.50M	2.17B

Hygeia Healthcare Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6078, the sentiment is Negative. The current price of 13 is below the 20-day moving average (MA) of 13.32, below the 50-day MA of 13.96, and below the 200-day MA of 14.78, indicating a bearish trend. The MACD of -0.29 indicates Negative momentum. The RSI at 37.89 is Neutral, neither overbought nor oversold. The STOCH value of 14.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6078.

Hygeia Healthcare Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3689	71 Outperform	HK$635.35M	7.70	5.33%	8.42%	0.47%	50.46%
1526	66 Neutral	HK$1.59B	5.48	20.47%	4.37%	-3.56%	-17.45%
2273	66 Neutral	HK$6.61B	18.11	14.86%	2.55%	16.41%	32.97%
6078	64 Neutral	HK$8.07B	16.42	6.78%	―	-13.92%	-36.32%
2373	63 Neutral	HK$6.92B	23.57	31.23%	1.79%	28.53%	22.34%
1951	55 Neutral	HK$6.59B	-6.32	-9.67%	2.50%	-8.56%	-403.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Hygeia Healthcare Holdings Co., Ltd. Corporate Events

Hygeia Healthcare Reports Decline in Revenue and Profit for H1 2025

Hygeia Healthcare Holdings Co., Ltd. announced its interim financial results for the six months ended June 30, 2025, reporting a revenue of RMB1,989.7 million, a decrease of 16.5% compared to the same period in 2024. The company’s net profit also declined by 36.2% to RMB245.8 million. Despite these decreases, the company saw a significant increase in net cash generated from operating activities, which rose by 29.9%, and a substantial rise in free cash flow by 1,611.2%. The decrease in interest-bearing liabilities by 5.1% indicates a positive step towards financial stability.

The most recent analyst rating on (HK:6078) stock is a Hold with a HK$16.50 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Announces 2025 Interim Results Presentation

Hygeia Healthcare Holdings Co., Ltd. announced a conference call scheduled for August 29, 2025, to present its 2025 interim results and business operations. The presentation aims to provide shareholders and potential investors with a comprehensive understanding of the company’s financial performance and operational status. The company emphasizes equal and timely access to information for all stakeholders and advises caution due to the presence of forward-looking statements in the presentation.

The most recent analyst rating on (HK:6078) stock is a Hold with a HK$16.50 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Schedules Board Meeting to Discuss Interim Results

Hygeia Healthcare Holdings Co., Ltd. has announced an upcoming board meeting scheduled for August 28, 2025. The meeting will focus on approving the interim results for the first half of 2025 and discussing the potential payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.

Hygeia Healthcare Issues Profit Warning Amid Industry Challenges

Hygeia Healthcare Holdings Co., Ltd. has issued a profit warning, indicating a significant decrease in revenue and net profit for the first half of 2025, primarily due to industry-wide factors such as centralized procurement and DRG payment method reform, as well as macroeconomic challenges. Despite these challenges, the company has managed to improve its cash flow and reduce liabilities, while enhancing technological capabilities and maintaining market competitiveness. The company remains confident in its long-term growth prospects and is focused on optimizing its revenue structure and operational efficiency.

The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.